Will Diseases Become More Predictable, Treatable and Curable?

Pan Chen

Albert Einstein College of Medicine, Forchheimer Building, 1300 Morris Park Ave, Bronx, USA

Editorial Note

With the development of modern medical and health services, our lifespan has and will continue to extend. However, along with the increased longevity, diseases associated with aging become a growing issue. Our immune system, cardiovascular system and nervous system are the primary systems showing the “wear and tear” of aging, giving rise to various life-threatening diseases, including cancers, heart attacks, stroke, Alzheimer’s disease (AD) and Parkinson’s disease (PD), to name a few. Although aging plays an important role in these diseases, gene-environment interactions become more and more critical, as with advanced age the genetic risk facilitates the unmasking of the diseases. Especially, neurological diseases will become more frequent as the nervous system does not regenerate as other systems do. Unfortunately, there are rare or no effective treatments for quite a few diseases, such as cancer, AD and PD. Understanding the pathology and etiology is the first step, with great achievements having taken place over the last few decades. Next, these research achievements must be translated into effective therapeutics or clinical treatments. New developments in translational biomedical research will allow us to predict disease onset, design effective treatments and eventually cure diseases.

Drug Development and Clinical Trials is launched as a multidisciplinary scientific journal to address all aspects of novel discoveries in pharmacology, biomedical techniques and clinical trials. This journal will cover the following research areas: (1) newly identified small molecules for corresponding diseases, (2) novel biotechniques improving diagnosis and clinical treatment, (3) more efficient drug delivery methods, (4) biomarkers or methods to predict disease onset, (5) clinical trials with detailed protocols, results and commentaries, to name a few. We expect this journal will be dedicated to current pharmacology development and clinical achievements, and convert them into practical application. With an internationally recognized editorial board, and a fast and fair peer review process, we will provide as comprehensive and multidisciplinary approach as possible to bring together original manuscripts covering the latest developments and scientific breakthroughs. The journal will provide information of great interest to physicians and biomedical researchers. We hope that the journal will offer valuable perspectives and inspire novel ideas in drug development and clinical applications. We are grateful to future contributors and hope the knowledge delivered in the journal will stimulate and translate novel ideas into better treatments in health and disease services.

We will create a timely, comprehensive and authoritative journal on today’s development in this field. As the journal grows and matures, we expect to make improvements in basic biomedical research as well as clinical and translational research, with the goal of bridging an introductory understanding with the latest clinical applications. I hope that the journal will offer a comprehensive and integrated understanding on current drug development and clinical trials, which benefits both students and experts in this field. I expect this Journal will inspire a deeper understanding and facilitate new collaborations, leading to improved treatment for diseases. With all our effort, I expect more diseases will become predictable, treatable and curable in the near future.

I look forward to our joined success.

Received Date: September 01, 2015, Accepted Date: September 02, 2015, Published Date: September 09, 2015.

*Corresponding author: Pan Chen, Albert Einstein College of Medicine, Forchheimer Building, Room 209, 1300 Morris Park Ave, Bronx, NY 10461, USA, Tel: 718-430-4047; E-mail: Pan.Chen@einstein.yu.edu

Copyright: © 2015 Pan Chen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.